PROQR THERAPEUTICS N.V. news, videos and press releases
For more news please use our advanced search feature.
PROQR THERAPEUTICS N.V. - More news...
PROQR THERAPEUTICS N.V. - More news...
- ProQR Announces Third Quarter 2024 Operating and Financial Results
- ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
- ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
- ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
- ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
- ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
- ProQR Announces Second Quarter 2024 Operating and Financial Results
- ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
- ProQR Therapeutics Provides Update on Ophthalmic Assets
- ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
- ProQR Announces Second Quarter 2023 Operating and Financial Results
- ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2023 Operating and Financial Results
- ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
- ProQR Announces Upcoming Investor Conferences in April and May
- ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
